



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of)

Inventor : Mary E. Abood)

U.S. Serial No.: 10/624,199)

Filed: July 21, 2003)

Title: USE OF ANANDAMIDE/
CANNABINOID RECEPTOR/
ACCEPTOR AGONISTS IN ALS
SCREENING AND TREATMENT
METHODS

Information Disclosure
Mail Stop Amendment)
Commissioner for Patents
P.O. BOX 1450
Alexandria VA 22313-1450

Group Art Unit: 1646

Examiner: Steven H. Stanley

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, addressed to Mail Stop Amendment, Commissioner for Patents, Box 1450, Alexandria VA 22313 on February 16, 2005.

Mary E. Abood 2/16/05
Mary E. Abood Date


7004 2510 0002 0406 9557

I submit this as a reference of interests that may represent prior art pertinent to application #10,624,199.

If additional fees are required for the filing of this document, the Commissioner for Patents is hereby authorized to charge to the address below.

Respectfully submitted,

Date: February 16, 2005

A handwritten signature in black ink, appearing to read "Mary E. Abood". The signature is fluid and cursive, with the first name "Mary" and last name "Abood" clearly distinguishable.

Mary E. Abood, Ph.D.
475 Brannan St Suite 220
San Francisco, CA 94107
Tel: 415-600-3607
FAX: 415-600-5970



INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/624,199
		Filing Date	July 21, 2003
		First Named Inventor	M. Abood
		Art Unit	1646
		Examiner Name	S. Stanley
Sheet 1	of 1	Attorney Docket Number	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Carter, GT and Rosen, BS. Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2001 18(4): 264-270	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.